{"transactions":[{"id":804385,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T21:19:30.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":132693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":132693,"derivative":{"exercise_price":24.52,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":132693},"source":{"system":"sec-edgar","filing":"0001193125-26-164308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000119312526164308/ownership.xml","form_type":"4"}},{"id":804384,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-04-20T21:19:30.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":76745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":735739,"source":{"system":"sec-edgar","filing":"0001193125-26-164308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000119312526164308/ownership.xml","form_type":"4"}},{"id":866020,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-03-04T00:06:19.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":54404,"price":22.8,"value":1240411.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 490 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":658994,"source":{"system":"sec-edgar","filing":"0001193125-26-089278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000119312526089278/ownership.xml","form_type":"4"}},{"id":866019,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-03-04T00:06:19.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":71177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics."}],"balance_after":712908,"source":{"system":"sec-edgar","filing":"0001193125-26-089278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000119312526089278/ownership.xml","form_type":"4"}},{"id":1227407,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-05T01:10:16.000Z","date":"2025-03-01","kind":"grant","planned":true,"acquired":true,"shares":78448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":78448,"derivative":{"exercise_price":42.92,"expiration_date":"2035-03-01","underlying":"Common Stock","underlying_shares":78448},"source":{"system":"sec-edgar","filing":"0000950170-25-032779","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000095017025032779/ownership.xml","form_type":"4"}},{"id":1227406,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-03-05T01:10:16.000Z","date":"2025-02-28","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":42.48,"value":1062000.0,"ownership":{"direct":false,"nature":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.89 to $42.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2158985,"source":{"system":"sec-edgar","filing":"0000950170-25-032779","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000095017025032779/ownership.xml","form_type":"4"}},{"id":1227405,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-03-05T01:10:16.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":73434,"price":42.1,"value":3091571.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":641731,"source":{"system":"sec-edgar","filing":"0000950170-25-032779","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000095017025032779/ownership.xml","form_type":"4"}},{"id":1227404,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-03-05T01:10:16.000Z","date":"2025-03-01","kind":"grant","planned":true,"acquired":true,"shares":107292,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric."}],"balance_after":715165,"source":{"system":"sec-edgar","filing":"0000950170-25-032779","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000095017025032779/ownership.xml","form_type":"4"}},{"id":1227403,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-03-05T01:10:16.000Z","date":"2025-03-01","kind":"grant","planned":true,"acquired":true,"shares":43268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"}],"balance_after":607873,"source":{"system":"sec-edgar","filing":"0000950170-25-032779","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000095017025032779/ownership.xml","form_type":"4"}},{"id":1319706,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-12-31T19:05:40.000Z","date":"2024-12-30","kind":"sale","planned":true,"acquired":false,"shares":11727,"price":42.23,"value":495231.21,"ownership":{"direct":false,"nature":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.58 to $43.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2183985,"source":{"system":"sec-edgar","filing":"0000950170-24-141485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000095017024141485/ownership.xml","form_type":"4"}},{"id":1335323,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-12-11T23:44:06.000Z","date":"2024-12-10","kind":"sale","planned":true,"acquired":false,"shares":8273,"price":50,"value":413650.0,"ownership":{"direct":false,"nature":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009"},"balance_after":2195712,"source":{"system":"sec-edgar","filing":"0000950170-24-135521","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000095017024135521/ownership.xml","form_type":"4"}},{"id":1335322,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-12-11T23:44:06.000Z","date":"2024-12-09","kind":"gift","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009"},"balance_after":2203985,"source":{"system":"sec-edgar","filing":"0000950170-24-135521","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000095017024135521/ownership.xml","form_type":"4"}},{"id":1413675,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-09-05T15:53:36.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":55.85,"value":1117000.0,"ownership":{"direct":false,"nature":"See FN"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.02 to $57.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009"}],"balance_after":2223985,"source":{"system":"sec-edgar","filing":"0000950170-24-103811","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000095017024103811/ownership.xml","form_type":"4"}},{"id":1438652,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-08-07T18:48:02.000Z","date":"2024-08-06","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":50.17,"value":1003400.0,"ownership":{"direct":false,"nature":"See FN"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009"}],"balance_after":2243985,"source":{"system":"sec-edgar","filing":"0000950170-24-092608","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000095017024092608/ownership.xml","form_type":"4"}},{"id":1595050,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T01:06:18.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":70094,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":70094,"derivative":{"exercise_price":53.69,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":70094},"source":{"system":"sec-edgar","filing":"0000950170-24-026625","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000095017024026625/ownership.xml","form_type":"4"}},{"id":1595049,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-03-06T01:06:18.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":3132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":563913,"source":{"system":"sec-edgar","filing":"0000950170-24-026625","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000095017024026625/ownership.xml","form_type":"4"}},{"id":1595048,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-03-06T01:06:18.000Z","date":"2024-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":17417,"price":53.69,"value":935118.73,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."}],"balance_after":560781,"source":{"system":"sec-edgar","filing":"0000950170-24-026625","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000095017024026625/ownership.xml","form_type":"4"}},{"id":1595047,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-03-06T01:06:18.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":38428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"}],"balance_after":578198,"source":{"system":"sec-edgar","filing":"0000950170-24-026625","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000095017024026625/ownership.xml","form_type":"4"}},{"id":1653217,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-02-08T20:49:34.000Z","date":"2024-02-07","kind":"sale","planned":false,"acquired":false,"shares":30000,"price":45,"value":1350000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.69 to $45.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":539770,"source":{"system":"sec-edgar","filing":"0001209191-24-002989","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919124002989/doc4.xml","form_type":"4"}},{"id":1696255,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-01-02T21:07:46.000Z","date":"2023-12-29","kind":"sale","planned":false,"acquired":false,"shares":30000,"price":47.87,"value":1436100.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.54 to $48.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 27 shares acquired under the Company's Amended and Restated 2014 Employee Stock Purchase Plan on October 31, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":569770,"source":{"system":"sec-edgar","filing":"0001209191-24-000071","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919124000071/doc4.xml","form_type":"4"}},{"id":1756163,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-23T21:14:33.000Z","date":"2023-10-19","kind":"exercise","planned":false,"acquired":false,"shares":47853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares thereafter such that the option fully vested on the fourth anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":6.86,"expiration_date":"2023-11-01","underlying":"Common Stock","underlying_shares":47853},"source":{"system":"sec-edgar","filing":"0001209191-23-053351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919123053351/doc4.xml","form_type":"4"}},{"id":1756162,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-10-23T21:14:33.000Z","date":"2023-10-19","kind":"sale","planned":false,"acquired":false,"shares":47853,"price":33.52,"value":1604032.56,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.57 to $34.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 567 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":599743,"source":{"system":"sec-edgar","filing":"0001209191-23-053351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919123053351/doc4.xml","form_type":"4"}},{"id":1756161,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-10-23T21:14:33.000Z","date":"2023-10-19","kind":"exercise","planned":false,"acquired":true,"shares":47853,"price":6.86,"value":328271.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023."}],"balance_after":647029,"source":{"system":"sec-edgar","filing":"0001209191-23-053351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919123053351/doc4.xml","form_type":"4"}},{"id":1972550,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-04T00:52:21.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":83500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":83500,"derivative":{"exercise_price":45.65,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":83500},"source":{"system":"sec-edgar","filing":"0001209191-23-016041","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919123016041/doc4.xml","form_type":"4"}},{"id":1972549,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-03-04T00:52:21.000Z","date":"2023-03-01","kind":"tax_withholding","acquired":false,"shares":16140,"price":45.65,"value":736791.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Reflects transfer of directly owned shares of common stock from the  Reporting Person to a trust indirectly held by the Reporting Person that have taken place since the most recent prior report on Form 4."}],"balance_after":599176,"source":{"system":"sec-edgar","filing":"0001209191-23-016041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919123016041/doc4.xml","form_type":"4"}},{"id":1972548,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-03-04T00:52:21.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":46200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."}],"balance_after":615606,"source":{"system":"sec-edgar","filing":"0001209191-23-016041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919123016041/doc4.xml","form_type":"4"}},{"id":1972547,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-03-04T00:52:21.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":8716,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric."}],"balance_after":569406,"source":{"system":"sec-edgar","filing":"0001209191-23-016041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919123016041/doc4.xml","form_type":"4"}},{"id":2072337,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-01-03T21:45:10.000Z","date":"2022-12-30","kind":"sale","acquired":false,"shares":19582,"price":45.57,"value":892351.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.94 to $46.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":541108,"source":{"system":"sec-edgar","filing":"0001209191-23-000276","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919123000276/doc4.xml","form_type":"4"}},{"id":2353582,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T23:06:25.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":92360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":92360,"derivative":{"exercise_price":67.37,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":92360},"source":{"system":"sec-edgar","filing":"0001209191-22-015799","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919122015799/doc4.xml","form_type":"4"}},{"id":2353581,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-03-03T23:06:25.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":52041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":634226,"source":{"system":"sec-edgar","filing":"0001209191-22-015799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919122015799/doc4.xml","form_type":"4"}},{"id":2353580,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-03-03T23:06:25.000Z","date":"2022-03-01","kind":"tax_withholding","acquired":false,"shares":12162,"price":67.37,"value":819353.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."}],"balance_after":582185,"source":{"system":"sec-edgar","filing":"0001209191-22-015799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919122015799/doc4.xml","form_type":"4"}},{"id":2419056,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-02-01T18:41:46.000Z","date":"2021-12-10","kind":"gift","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200"},"balance_after":2209741,"source":{"system":"sec-edgar","filing":"0001209191-22-005839","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919122005839/doc5.xml","form_type":"5"}},{"id":2540418,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-10-18T22:44:19.000Z","date":"2021-10-14","kind":"tax_withholding","acquired":false,"shares":853,"price":81,"value":69093.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":594347,"source":{"system":"sec-edgar","filing":"0001209191-21-060749","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919121060749/doc4.xml","form_type":"4"}},{"id":2720702,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-05-10T22:11:25.000Z","date":"2021-05-06","kind":"tax_withholding","acquired":false,"shares":852,"price":115.71,"value":98584.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":595200,"source":{"system":"sec-edgar","filing":"0001209191-21-031383","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919121031383/doc4.xml","form_type":"4"}},{"id":2726882,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-05-05T15:32:18.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":30000,"price":107.8,"value":3234000.0,"ownership":{"direct":false,"nature":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.14 to $110.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2259741,"source":{"system":"sec-edgar","filing":"0001209191-21-030211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919121030211/doc4.xml","form_type":"4"}},{"id":2812369,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-04T01:36:55.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":36000,"derivative":{"exercise_price":142.47,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001209191-21-017537","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919121017537/doc4.xml","form_type":"4"}},{"id":2812368,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-03-04T01:36:55.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":30000,"price":141.8,"value":4254000.0,"ownership":{"direct":false,"nature":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.89 to $143.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2289741,"source":{"system":"sec-edgar","filing":"0001209191-21-017537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919121017537/doc4.xml","form_type":"4"}},{"id":2812367,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-03-04T01:36:55.000Z","date":"2021-03-01","kind":"tax_withholding","acquired":false,"shares":16342,"price":142.47,"value":2328244.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":596052,"source":{"system":"sec-edgar","filing":"0001209191-21-017537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919121017537/doc4.xml","form_type":"4"}},{"id":2812366,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-03-04T01:36:55.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":15453,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents 5,099 shares of common stock and 10,354 RSUs into which previously granted performance stock units were converted on March 1, 2021 upon certification of the performance metric. The RSUs will fully vest on March 1, 2022."}],"balance_after":612394,"source":{"system":"sec-edgar","filing":"0001209191-21-017537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919121017537/doc4.xml","form_type":"4"}},{"id":2812365,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-03-04T01:36:55.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."}],"balance_after":596941,"source":{"system":"sec-edgar","filing":"0001209191-21-017537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919121017537/doc4.xml","form_type":"4"}},{"id":2881274,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-04T01:03:18.000Z","date":"2020-11-27","kind":"gift","acquired":false,"shares":31248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":578941,"source":{"system":"sec-edgar","filing":"0001209191-21-007554","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919121007554/doc5.xml","form_type":"5"}},{"id":2881273,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-04T01:03:18.000Z","date":"2020-05-27","kind":"gift","acquired":false,"shares":40422,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":578941,"source":{"system":"sec-edgar","filing":"0001209191-21-007554","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919121007554/doc5.xml","form_type":"5"}},{"id":2881272,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-04T01:03:18.000Z","date":"2020-11-19","kind":"gift","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009"},"balance_after":2349741,"source":{"system":"sec-edgar","filing":"0001209191-21-007554","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919121007554/doc5.xml","form_type":"5"}},{"id":2881271,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-04T01:03:18.000Z","date":"2020-05-22","kind":"gift","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009"},"balance_after":2349741,"source":{"system":"sec-edgar","filing":"0001209191-21-007554","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919121007554/doc5.xml","form_type":"5"}},{"id":2919891,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-01-05T23:45:45.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":30000,"price":136.9,"value":4107000.0,"ownership":{"direct":false,"nature":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.66 to $138.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2329741,"source":{"system":"sec-edgar","filing":"0001209191-21-001583","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919121001583/doc4.xml","form_type":"4"}},{"id":2992477,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-11-04T20:44:05.000Z","date":"2020-11-02","kind":"sale","acquired":false,"shares":30000,"price":96.82,"value":2904600.0,"ownership":{"direct":false,"nature":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $100.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2359741,"source":{"system":"sec-edgar","filing":"0001209191-20-056859","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919120056859/doc4.xml","form_type":"4"}},{"id":3005033,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-10-16T23:23:04.000Z","date":"2020-10-14","kind":"tax_withholding","acquired":false,"shares":852,"price":92.69,"value":78971.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":610189,"source":{"system":"sec-edgar","filing":"0001209191-20-055182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919120055182/doc4.xml","form_type":"4"}},{"id":3040851,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-09-02T20:26:27.000Z","date":"2020-09-01","kind":"sale","acquired":false,"shares":30000,"price":82.63,"value":2478900.0,"ownership":{"direct":false,"nature":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.51 to $85.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2389741,"source":{"system":"sec-edgar","filing":"0001209191-20-049130","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919120049130/doc4.xml","form_type":"4"}},{"id":3082526,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-07-15T17:22:40.000Z","date":"2020-07-13","kind":"sale","acquired":false,"shares":40000,"price":85.35,"value":3414000.0,"ownership":{"direct":false,"nature":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.74 to $87.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2419741,"source":{"system":"sec-edgar","filing":"0001209191-20-042479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919120042479/doc4.xml","form_type":"4"}},{"id":3123605,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-06-03T18:17:27.000Z","date":"2020-06-01","kind":"tax_withholding","acquired":false,"shares":1334,"price":69.38,"value":92552.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The amount set forth in column 5 reflects dispositions from gifts that will be reported in a Form 5 within 45 days after the Issuer's fiscal year end."}],"balance_after":611041,"source":{"system":"sec-edgar","filing":"0001209191-20-033883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919120033883/doc4.xml","form_type":"4"}},{"id":3156179,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-09T00:06:31.000Z","date":"2020-05-06","kind":"tax_withholding","acquired":false,"shares":852,"price":66.26,"value":56453.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":652797,"source":{"system":"sec-edgar","filing":"0001209191-20-028114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919120028114/doc4.xml","form_type":"4"}},{"id":3172373,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-04-21T19:34:47.000Z","date":"2020-04-19","kind":"tax_withholding","acquired":false,"shares":851,"price":58.57,"value":49843.07,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":653649,"source":{"system":"sec-edgar","filing":"0001209191-20-025189","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919120025189/doc4.xml","form_type":"4"}},{"id":3210711,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Warrant (Right to Buy)","published_at":"2020-03-13T16:59:39.000Z","date":"2020-03-12","kind":"other","acquired":false,"shares":66533,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.006,"exercise_date":"2011-06-14","expiration_date":"2021-06-14","underlying":"Common Stock","underlying_shares":66533},"source":{"system":"sec-edgar","filing":"0001209191-20-018749","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919120018749/doc4.xml","form_type":"4"}},{"id":3210710,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Warrant (Right to Buy)","published_at":"2020-03-13T16:59:39.000Z","date":"2020-03-12","kind":"other","acquired":false,"shares":83167,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.006,"exercise_date":"2010-06-30","expiration_date":"2020-06-30","underlying":"Common Stock","underlying_shares":83167},"source":{"system":"sec-edgar","filing":"0001209191-20-018749","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919120018749/doc4.xml","form_type":"4"}},{"id":3210709,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-03-13T16:59:39.000Z","date":"2020-03-12","kind":"other","acquired":true,"shares":66533,"price":3.006,"value":199998.198,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":654500,"source":{"system":"sec-edgar","filing":"0001209191-20-018749","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919120018749/doc4.xml","form_type":"4"}},{"id":3210708,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-03-13T16:59:39.000Z","date":"2020-03-12","kind":"other","acquired":true,"shares":83167,"price":3.006,"value":250000.002,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":587967,"source":{"system":"sec-edgar","filing":"0001209191-20-018749","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919120018749/doc4.xml","form_type":"4"}},{"id":3231560,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-04T00:58:22.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":56100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":56100,"derivative":{"exercise_price":56.08,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":56100},"source":{"system":"sec-edgar","filing":"0001209191-20-015760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919120015760/doc4.xml","form_type":"4"}},{"id":3231559,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-03-04T00:58:22.000Z","date":"2020-03-01","kind":"tax_withholding","acquired":false,"shares":6896,"price":56.08,"value":386727.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":504800,"source":{"system":"sec-edgar","filing":"0001209191-20-015760","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919120015760/doc4.xml","form_type":"4"}},{"id":3231558,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-03-04T00:58:22.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":18782,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents 6,198 shares of common stock and 12,584 RSUs which previously granted performance stock units were converted on March 1, 2020 upon certification of the performance metric.  The RSUs will fully vest on March 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":511696,"source":{"system":"sec-edgar","filing":"0001209191-20-015760","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919120015760/doc4.xml","form_type":"4"}},{"id":3231557,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-03-04T00:58:22.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":492914,"source":{"system":"sec-edgar","filing":"0001209191-20-015760","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919120015760/doc4.xml","form_type":"4"}},{"id":3392783,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-10-16T23:30:26.000Z","date":"2019-10-14","kind":"grant","acquired":true,"shares":3435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on October 14, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":475914,"source":{"system":"sec-edgar","filing":"0001209191-19-053326","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919119053326/doc4.xml","form_type":"4"}},{"id":3417322,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-09-11T16:35:25.000Z","date":"2019-09-11","kind":"purchase","acquired":true,"shares":5000,"price":43.63,"value":218150.0,"ownership":{"direct":true},"balance_after":472479,"source":{"system":"sec-edgar","filing":"0001209191-19-049117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919119049117/doc4.xml","form_type":"4"}},{"id":3502006,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-06-04T22:59:11.000Z","date":"2019-06-01","kind":"tax_withholding","acquired":false,"shares":1327,"price":54.93,"value":72892.11,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":467479,"source":{"system":"sec-edgar","filing":"0001209191-19-034552","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919119034552/doc4.xml","form_type":"4"}},{"id":3514946,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-22T21:44:52.000Z","date":"2019-05-21","kind":"tax_withholding","acquired":false,"shares":1414,"price":59.5,"value":84133.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":468806,"source":{"system":"sec-edgar","filing":"0001209191-19-032138","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919119032138/doc4.xml","form_type":"4"}},{"id":3536365,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-07T22:57:05.000Z","date":"2019-05-06","kind":"grant","acquired":true,"shares":3435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on May 6, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":470220,"source":{"system":"sec-edgar","filing":"0001209191-19-028093","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919119028093/doc4.xml","form_type":"4"}},{"id":3551020,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-04-23T22:41:12.000Z","date":"2019-04-19","kind":"tax_withholding","acquired":false,"shares":798,"price":64.43,"value":51415.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":466785,"source":{"system":"sec-edgar","filing":"0001209191-19-025622","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919119025622/doc4.xml","form_type":"4"}},{"id":3553485,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-17T21:38:26.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":66000,"derivative":{"exercise_price":67.55,"expiration_date":"2029-03-01","underlying":"Common Stock","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001209191-19-025069","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919119025069/doc4a.xml","form_type":"4/A","original_submission_date":"2019-03-04"}},{"id":3553484,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-04-17T21:38:26.000Z","date":"2019-03-05","kind":"sale","acquired":false,"shares":2890,"price":65.52,"value":189352.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units."}],"balance_after":467583,"source":{"system":"sec-edgar","filing":"0001209191-19-025069","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919119025069/doc4a.xml","form_type":"4/A","original_submission_date":"2019-03-04"}},{"id":3553483,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-04-17T21:38:26.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":470473,"source":{"system":"sec-edgar","filing":"0001209191-19-025069","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919119025069/doc4a.xml","form_type":"4/A","original_submission_date":"2019-03-04"}},{"id":3618470,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-04T22:00:23.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":66000,"derivative":{"exercise_price":67.55,"expiration_date":"2029-03-01","underlying":"Common Stock","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001209191-19-015726","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919119015726/doc4.xml","form_type":"4"}},{"id":3618469,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-03-04T22:00:23.000Z","date":"2019-03-01","kind":"tax_withholding","acquired":false,"shares":2802,"price":67.55,"value":189275.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."}],"balance_after":467670,"source":{"system":"sec-edgar","filing":"0001209191-19-015726","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919119015726/doc4.xml","form_type":"4"}},{"id":3618468,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-03-04T22:00:23.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":470472,"source":{"system":"sec-edgar","filing":"0001209191-19-015726","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919119015726/doc4.xml","form_type":"4"}},{"id":3908022,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-06-04T20:45:48.000Z","date":"2018-06-01","kind":"tax_withholding","acquired":false,"shares":926,"price":73.73,"value":68273.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":450472,"source":{"system":"sec-edgar","filing":"0001209191-18-035161","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919118035161/doc4.xml","form_type":"4"}},{"id":3921823,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-05-22T15:42:42.000Z","date":"2018-05-21","kind":"tax_withholding","acquired":false,"shares":986,"price":64.79,"value":63882.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":451398,"source":{"system":"sec-edgar","filing":"0001209191-18-032206","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919118032206/doc4.xml","form_type":"4"}},{"id":3959977,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-04-19T20:42:07.000Z","date":"2018-04-19","kind":"grant","acquired":true,"shares":3429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on April 19, 2018 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":452384,"source":{"system":"sec-edgar","filing":"0001209191-18-025586","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919118025586/doc4.xml","form_type":"4"}},{"id":4014424,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-05T21:12:59.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":94500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":94500,"derivative":{"exercise_price":48.43,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":94500},"source":{"system":"sec-edgar","filing":"0001209191-18-016405","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919118016405/doc4.xml","form_type":"4"}},{"id":4014423,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-03-05T21:12:59.000Z","date":"2018-03-01","kind":"tax_withholding","acquired":false,"shares":1114,"price":48.43,"value":53951.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."}],"balance_after":448955,"source":{"system":"sec-edgar","filing":"0001209191-18-016405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919118016405/doc4.xml","form_type":"4"}},{"id":4014422,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-03-05T21:12:59.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":450069,"source":{"system":"sec-edgar","filing":"0001209191-18-016405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919118016405/doc4.xml","form_type":"4"}},{"id":4222391,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-08-29T20:30:04.000Z","date":"2017-08-28","kind":"purchase","acquired":true,"shares":1647,"price":52.96,"value":87225.12,"ownership":{"direct":false,"nature":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $52.90 to $52.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":2559741,"source":{"system":"sec-edgar","filing":"0001209191-17-050586","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919117050586/doc4.xml","form_type":"4"}},{"id":4222390,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-08-29T20:30:04.000Z","date":"2017-08-28","kind":"purchase","acquired":true,"shares":5853,"price":52.4,"value":306697.2,"ownership":{"direct":false,"nature":"By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $51.89 to $52.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":2558094,"source":{"system":"sec-edgar","filing":"0001209191-17-050586","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919117050586/doc4.xml","form_type":"4"}},{"id":4297878,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-06-02T01:14:32.000Z","date":"2017-06-01","kind":"tax_withholding","acquired":false,"shares":1006,"price":56.61,"value":56949.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units."}],"balance_after":430569,"source":{"system":"sec-edgar","filing":"0001209191-17-036973","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919117036973/doc4.xml","form_type":"4"}},{"id":4309755,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-05-22T23:04:29.000Z","date":"2017-05-21","kind":"tax_withholding","acquired":false,"shares":1072,"price":57.47,"value":61607.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units."}],"balance_after":431575,"source":{"system":"sec-edgar","filing":"0001209191-17-034491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919117034491/doc4.xml","form_type":"4"}},{"id":4413637,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-03-01T22:42:56.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":78000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":78000,"derivative":{"exercise_price":88.8,"expiration_date":"2027-03-01","underlying":"Common Stock","underlying_shares":78000},"source":{"system":"sec-edgar","filing":"0001209191-17-016065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919117016065/doc4.xml","form_type":"4"}},{"id":4413636,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-03-01T22:42:56.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":432647,"source":{"system":"sec-edgar","filing":"0001209191-17-016065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919117016065/doc4.xml","form_type":"4"}},{"id":4456956,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-02-10T23:00:34.000Z","date":"2016-12-22","kind":"gift","acquired":false,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":419647,"source":{"system":"sec-edgar","filing":"0001209191-17-009699","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000120919117009699/doc5.xml","form_type":"5"}},{"id":4550125,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2016-11-17T21:01:05.000Z","date":"2016-11-15","kind":"sale","acquired":false,"shares":200,"price":83.01,"value":16602.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.00 to $83.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":447147,"source":{"system":"sec-edgar","filing":"0001562180-16-003561","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000156218016003561/primarydocument.xml","form_type":"4"}},{"id":4550124,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2016-11-17T21:01:05.000Z","date":"2016-11-15","kind":"sale","acquired":false,"shares":4180,"price":82.36,"value":344264.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.00 to $82.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":447347,"source":{"system":"sec-edgar","filing":"0001562180-16-003561","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000156218016003561/primarydocument.xml","form_type":"4"}},{"id":4550123,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2016-11-17T21:01:05.000Z","date":"2016-11-15","kind":"sale","acquired":false,"shares":7755,"price":81.55,"value":632420.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":451527,"source":{"system":"sec-edgar","filing":"0001562180-16-003561","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000156218016003561/primarydocument.xml","form_type":"4"}},{"id":4550122,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2016-11-17T21:01:05.000Z","date":"2016-11-15","kind":"sale","acquired":false,"shares":6451,"price":80.64,"value":520208.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.97 to $80.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":459282,"source":{"system":"sec-edgar","filing":"0001562180-16-003561","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000156218016003561/primarydocument.xml","form_type":"4"}},{"id":4550121,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2016-11-17T21:01:05.000Z","date":"2016-11-15","kind":"sale","acquired":false,"shares":1414,"price":79.39,"value":112257.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.97 to $79.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":465733,"source":{"system":"sec-edgar","filing":"0001562180-16-003561","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000156218016003561/primarydocument.xml","form_type":"4"}},{"id":4578153,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2016-10-18T20:01:08.000Z","date":"2016-10-14","kind":"sale","acquired":false,"shares":1800,"price":64.78,"value":116604.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.67 to $64.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":467147,"source":{"system":"sec-edgar","filing":"0001562180-16-003247","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000156218016003247/primarydocument.xml","form_type":"4"}},{"id":4578152,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2016-10-18T20:01:08.000Z","date":"2016-10-14","kind":"sale","acquired":false,"shares":2345,"price":64.41,"value":151041.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.65 to $64.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":468947,"source":{"system":"sec-edgar","filing":"0001562180-16-003247","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000156218016003247/primarydocument.xml","form_type":"4"}},{"id":4578151,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2016-10-18T20:01:08.000Z","date":"2016-10-14","kind":"sale","acquired":false,"shares":9340,"price":63.06,"value":588980.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.57 to $63.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":471292,"source":{"system":"sec-edgar","filing":"0001562180-16-003247","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000156218016003247/primarydocument.xml","form_type":"4"}},{"id":4578150,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2016-10-18T20:01:08.000Z","date":"2016-10-14","kind":"sale","acquired":false,"shares":6515,"price":61.97,"value":403734.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.57 to $62.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":480632,"source":{"system":"sec-edgar","filing":"0001562180-16-003247","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000156218016003247/primarydocument.xml","form_type":"4"}}]}